Barclays PLC Zentalis Pharmaceuticals, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 75,395 shares of ZNTL stock, worth $239,756. This represents 0.0% of its overall portfolio holdings.

Number of Shares

75,395

Previous 75,395 -0.0%

Holding current value

$239,756

Previous $277,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$2.9 - $4.57 $34,069 - $53,688	11,748 Added 18.46%	75,395 $277,000
Q2 2024 Aug 14, 2024	SELL	$4.09 - $16.13 $10,920 - $43,067	-2,670 Reduced 4.03%	63,647 $261,000
Q1 2024 May 15, 2024	SELL	$10.83 - $16.49 $1.66 Million - $2.53 Million	-153,201 Reduced 69.79%	66,317 $1.05 Million
Q4 2023 Feb 15, 2024	BUY	$9.84 - $20.13 $1.07 Million - $2.19 Million	108,701 Added 98.09%	219,518 $3.33 Million
Q3 2023 Nov 07, 2023	SELL	$19.63 - $28.29 $1.99 Million - $2.87 Million	-101,598 Reduced 47.83%	110,817 $2.22 Million
Q2 2023 Aug 03, 2023	BUY	$17.41 - $30.05 $2.13 Million - $3.68 Million	122,451 Added 136.11%	212,415 $5.99 Million
Q1 2023 May 04, 2023	SELL	$16.14 - $24.94 $611,867 - $945,475	-37,910 Reduced 29.65%	89,964 $1.55 Million
Q4 2022 Feb 13, 2023	BUY	$18.07 - $25.6 $203,757 - $288,665	11,276 Added 9.67%	127,874 $2.58 Million
Q3 2022 Nov 03, 2022	BUY	$20.23 - $31.73 $2.29 Million - $3.59 Million	113,153 Added 3284.56%	116,598 $2.53 Million
Q2 2022 Aug 12, 2022	SELL	$17.91 - $52.25 $61,055 - $178,120	-3,409 Reduced 49.74%	3,445 $97,000
Q1 2022 May 16, 2022	BUY	$41.58 - $80.89 $284,989 - $554,420	6,854 New	6,854 $316,000

Others Institutions Holding ZNTL

# of Institutions

142

Shares Held

67.9M

Call Options Held

48.5K

Put Options Held

89.6K

View Full List

About Zentalis Pharmaceuticals, Inc.

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $181M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

More about ZNTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account